Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Creatinine
/ therapeutic use
Fever
/ etiology
Humans
Imidazoles
/ adverse effects
Male
Melanoma
/ etiology
Middle Aged
Mitogen-Activated Protein Kinase Kinases
Mutation
Myositis
/ chemically induced
Oximes
/ adverse effects
Protein Kinase Inhibitors
/ adverse effects
Proto-Oncogene Proteins B-raf
/ genetics
Pyridones
Pyrimidinones
/ adverse effects
Skin Neoplasms
/ etiology
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
1
6
2022
medline:
6
7
2022
entrez:
31
5
2022
Statut:
ppublish
Résumé
The effect of serine/threonine-protein kinase B-Raf/mitogen-activated protein kinase (BRAF/MEK) inhibitors on the immune system is not clearly described, but rare cases of autoimmune phenomena have been reported. The clinical case we present below is the first report of a necrotizing myopathy related to dabrafenib/trametinib treatment. A 48-year-old man started dabrafenib/trametinib for stage IV BRAF-V600E mutated cutaneous melanoma. After the first month, he presented with grade 3 pyrexia (Common Terminology Criteria for Adverse Events [CTCAE] v.5.0.) and increased creatinine-kinase levels. A diagnosis of immune-mediated necrotizing myopathy, antisignal recognition particle (anit-SRP) positive, was made. At disease progression, dabrafenib/trametinib was restarted, triggering a new episode of grade 2 pyrexia and myositis. Treatment was changed to encorafenib/binimetinib without repeating pyrexia or limiting creatinine-kinase elevation, presenting even a loss of anti-SRP antibodies. Given the temporal relationship, the fact that re-exposition induced a new worsening of the myopathy and the loss of the anti-SRP antibodies after changing treatment, we infer that there possibly is a clear relationship between dabrafenib/trametinib treatment and the myopathy.
Identifiants
pubmed: 35635528
doi: 10.1097/CMR.0000000000000831
pii: 00008390-202208000-00012
doi:
Substances chimiques
Imidazoles
0
Oximes
0
Protein Kinase Inhibitors
0
Pyridones
0
Pyrimidinones
0
Creatinine
AYI8EX34EU
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
299-301Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016; 17:1248–1260.
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19:603–615.
Kim HY, Duong JK, Gonzalez M, Long GV, Menzies AM, Rizos H, et al. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Cancer Chemother Pharmacol. 2019; 83:693–704.
Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006; 65:1635–1638.
Hara A, Amano R, Yokote H, Ijima M, Zeniya S, Uchihara T, et al. Secondary cardiac involvement in anti-SRP-antibody-positive myopathy: an 87-year-old woman with heart failure symptoms as the first clinical presentation. BMC Neurol. 2020; 20:29.
Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015; 10:61.
Below S, Bashir M. SRP-positive necrotising myopathy: takes more than just the muscles. BMJ Case Rep. 2021; 14:e237647.
Ajiboye O, Manesh M, Asmi N, Mba B. Atypical presentation of necrotising autoimmune myopathy. BMJ Case Rep. 2019; 12:e229119.
O’Grady J, Harty L, Mayer N, Critcher V, Ryan J. Immune-mediated necrotizing myopathy, associated with antibodies to signal recognition particle, together with lupus nephritis: case presentation and management. J Clin Med Res. 2015; 7:490–494.
Fernandes das Neves M, Caetano J, Oliveira S, Delgado Alves J. Immune-mediated necrotising myopathy associated with antibodies to the signal recognition particle treated with a combination of rituximab and cyclophosphamide. BMJ Case Rep. 2015; 2015:bcr2014206250.